Journal Paper

Effects of Alogliptin on hypertensive chronic kidney disease with Type 2 diabetes mellitus

مايو 03, 2018

DOI: 10.21767/AMJ.2018.3319

Publisher: Australasian medical journal

/ Amira Shaaban / Nadia Hussain Farideh Javaid

Background: Diabetes mellitus(DM)is a leading cause of chronic kidney disease (CKD). Theantihyperglycemic treatment options for patients with Type 2 DM are limited because of safety and tolerability concerns. Aims: To retrospectively assess the effect of using Alogliptin; a dipeptidyl peptidase-4 inhibitor (DPP-4i) alongwith conventional gliclazide: a sulphonylurea (SU) on renal outcomes and glycaemiccontrol in T2DM patients with mildCKDand hypertension. Methods: A total of 76 patient records (38 males and 38 females) of patient ages 40–60 were analysed from the kidney unit at Punjab Care hospital, Lahore, Pakistan. All patients had a confirmed history of T2DM with mild CKD and established hypertension.Eligible patients were divided into two groups of 38 individuals each. Group SU received gliclazide monotherapy (SU) or Alogliptin (DPP-4i)+gliclazide (SU) add on therapy. All patients were followed up for 12 months.ResultsThe alogliptin (DPP-4i) plus gliclazide (SU) add on therapy group, in comparison to the group only receiving gliclazide (SU), showed a significant difference in eGFR values. The mean±SD GFR values post 12 months were 74.8±0.31(95%CI:74.8±0.09;74.7–74.9) and 76.1±0.25(95%CI: 76.1±0.08;76.0-76.2) for SU vs.SU+DPP-4i, respectively, with mean calculated effect size of 1.6,.HbA1c, 1,5 AG and ipid profile values have significantly changed(p<0.05) while blood pressure values showed no change. The mean±SD systolic blood pressure readings post 12 months for for SU vs.SU+DPP-4i were 131.4±10.4 (95% CI 131.4±3.3;128.1–134.7), and 131.8±9.9 (95%CI 131.8±3; 128.8–134.8), respectively. Conclusion: In the present study, patients using alogliptin in addition to sulfonyl urea showed improved glycaemic control and lipid profile without increased occurrence of hypoglycaemia. We concluded that, DPP-4iinhibitors are safe treatment options for patients with type 2 diabetes and mild degree of renal impairment.

Other Researches

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Abstract Aim. To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastati...

Knowledge, attitude, and practice analysis of corticosteroid use among patients: A study based in the United Arab Emirates

Background: Corticosteroids (CS) have long been known as the most powerful of all known anti-inflammatory agents. Since their introduction in 1949, they have shown pivotal role in the treatment of various serious disorders such as autoimmune disease...